Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) CFO Paul J. Mellett sold 2,412 shares of the firm’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $9.63, for a total value of $23,227.56. Following the sale, the chief financial officer now directly owns 93,549 shares in […]
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating)’s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as $22.80 and last traded at $23.75, with a volume of 211387 shares trading hands. The stock had previously closed at $23.80. Analysts Set New Price Targets ENTA has been the […]
StockNews.com initiated coverage on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) in a research note published on Thursday. The firm issued a hold rating on the biotechnology company’s stock. Several other research firms have also recently commented on ENTA. JPMorgan Chase & Co. cut their price target on Enanta Pharmaceuticals from $74.00 to $60.00 […]
StockNews.com began coverage on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) in a report released on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock. A number of other brokerages have also issued reports on ENTA. Piper Sandler reiterated an overweight rating and set a $87.00 target price on shares […]
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price objective […]